Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
| ▸ | KRAS | P01116 | 6/20 | 0.47 |
| ▸ | DTYMK | P23919 | 4/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22053473 | 1.00 | POLB (0.67) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL24219865 | 0.95 | POLB (0.71) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL20832611 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL20832612 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL20832619 | 0.88 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL20710403 | 0.88 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL22053475 | 0.88 | POLB (0.81) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL542729 | 0.88 | P2RY2 (0.67) | POLBP2RY2P2RY4P2RY6NT5E | |
| Guadecitabine SCHEMBL23510987 | 0.86 | POLB (0.66) | POLBP2RY2P2RY4P2RY6NT5E | |
| Guadecitabine SCHEMBL23234155 | 0.86 | POLB (0.66) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858386-B2 | Drug compound and purification methods thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20200172565-A1 | DRUG COMPOUND AND PURIFICATION METHODS THEREOF | ASTEX PHARMACEUTICALS, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858386-B2 | Drug compound and purification methods thereof | SRMS, TREH, SYMPK | POLB 2788/4885P2RY2 3432/4885P2RY4 2241/4885 |
| US-20200172565-A1 | DRUG COMPOUND AND PURIFICATION METHODS THEREOF | SRMS, TREH, SYMPK | POLB 2788/4885P2RY2 3432/4885P2RY4 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.